Premium
Pharmacokinetics of mosapride citrate in patients with gastrectomy
Author(s) -
Kumagai Y.,
Fujita T.,
Ozaki M.,
Ohtani Y.,
Majima M.
Publication year - 2005
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1016/j.clpt.2004.12.085
Subject(s) - gastrectomy , pharmacokinetics , medicine , gastroenterology , cancer
Backgrounds Mosapride citrate is a selective 5‐HT4 receptor agonist which is used as a gastroprokinetic drug in Japan. It is expected that mosapride citrate alleviate gastrointestinal symptom in patients with postgastrectomy. However, solubility of the drug is decreased with increase of pH and in a dog model of distal partial gastrectomy, absorption of the drug is decreased. We studied pharmacokinetics of mosapride in patients operated by gastrectomy. Methods Eight healthy male volunteers, 8 male subjects with distal gastrectomy and 8 male subjects with total gastrectomy were included. Mosapride citrate 10mg was administered orally in the morning after overnight fast, and the plasma concentration of the drug were measured. Pharmacokinetic parameters such as maximum concentration (Cmax), time to reach Cmax, elimination half‐life and area under the curve (AUC) were calculated and compared by Student's t‐test. Results There was a tendency that Cmax and AUC are low in the total gastrectomy group compared with healthy group without statistical significance. There also found no significant change in other parameters. Conclusion Pharmacokinetics of mosapride did not change in the group operated by distal or total gastrectomy. Clinical Pharmacology & Therapeutics (2005) 77 , P51–P51; doi: 10.1016/j.clpt.2004.12.085